SABS

SAB Biotherapeutics, Inc.

Price Chart

Latest Quote

$4.00

+0.14 (+3.63%)

Current Price

Previous Close	$3.86
Open	$3.93
Day High	$4.10
Day Low	$3.85
Volume	2,359,954

Fetched: 2026-06-19T17:43:46

Stock Information

Shares Outstanding	76.46M
Total Debt	$6.17M
Cash Equivalents	$107.39M
Net Income	$-9.41M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$305.86M
EPS (TTM)	$-0.58
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$204.64M
Income	$-9.41M
Book/sh	$3.00
Cash/sh	$1.40
Employees	86

Financial Ratios

Quick Ratio	11.06
Current Ratio	11.45
Debt/Eq	2.72

Returns & Margins

ROA	-25.37%
ROE	-0.32%

Ownership

Insider Ownership	0.84%
Institutional Ownership	91.88%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-4.48
P/B	1.33

Analyst Data

Recommendation	strong_buy
Target Price	$11.00

Technical Indicators

SMA20	$3.58
SMA50	$3.69
SMA200	$3.51
RSI	60.53
ATR	0.2454

Shares Float	52.34M
Short Float	3.59%
Short Ratio	2.63
Rel Volume	3.46

Performance History

Week	+18.34%
Month	+12.68%
Quarter	+5.82%
6 Months	+0.25%
YTD	+6.10%
Year	+124.72%
3 Years	-54.29%
5 Years	-95.98%
10 Years	-96.06%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$4.00	2,908,300
2026-06-17	$3.86	712,600
2026-06-16	$3.66	1,921,500
2026-06-15	$3.90	5,977,100
2026-06-12	$3.33	355,800
2026-06-11	$3.38	239,800
2026-06-10	$3.31	214,300
2026-06-09	$3.36	362,600
2026-06-08	$3.40	349,000
2026-06-05	$3.38	351,600
2026-06-04	$3.47	304,000
2026-06-03	$3.36	327,000
2026-06-02	$3.48	473,900
2026-06-01	$3.44	529,800
2026-05-29	$3.60	223,700
2026-05-28	$3.57	133,800
2026-05-27	$3.60	283,200
2026-05-26	$3.81	447,400
2026-05-22	$3.90	324,100
2026-05-21	$3.81	373,600
2026-05-20	$3.68	565,700
2026-05-19	$3.55	488,000

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

📰 Latest News

Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization

Insider Monkey • 2026-05-20T20:43:44Z

We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully

Simply Wall St. • 2026-05-15T11:32:16Z

SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

GuruFocus.com • 2026-05-12T23:03:26Z

SAB Biotherapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-12T17:14:24Z

SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf

MarketBeat • 2026-03-01T19:43:57Z

SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026

MarketBeat • 2026-02-15T06:05:34Z

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

TipRanks • 2026-01-25T11:05:00Z

SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week

Simply Wall St. • 2025-11-22T12:27:25Z

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks • 2025-08-07T14:00:05Z

SAB Biotherapeutics Raises $175 Million in Oversubscribed Private Placement; Shares Rise Pre-Bell

MT Newswires • 2025-07-21T12:07:08Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$240,664	$318,401	$315,284	$301,584
Total Expenses	$48,953,363	$42,910,520	$38,075,320	$28,917,617
Other Income Expense	$61,035,678	$7,837,614	$-4,388,148	$10,432,954
Other Non Operating Income Expenses	$-1,718,508	$2,452,605	$435,089	$33,754
Net Non Operating Interest Income Expense	$1,191,368	$967,597	$269,682	$-230,512
Interest Expense Non Operating	$240,664	$318,401	$315,284	$301,584
Operating Expense	$48,953,363	$42,910,520	$38,075,320	$28,917,617
General And Administrative Expense	$14,601,031	$13,981,263	$23,799,306	$16,383,285
Other Operating Expenses	-	$-1,322,410	$-2,238,991	$-23,904,181
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Net Interest Income	$1,191,368	$967,597	$269,682	$-230,512
Interest Income	$1,432,032	$1,285,998	$584,966	$71,072
Normalized Income	$-49,480,503	$-39,490,318	$-37,370,549	$-26,956,172
Net Income From Continuing And Discontinued Operation	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Total Operating Income As Reported	$-48,953,363	$-42,910,520	$-38,075,320	$-28,917,617
Average Dilution Earnings	$-62,000,073	$0	-	-
Net Income Common Stockholders	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Net Income	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Net Income Including Noncontrolling Interests	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Net Income Continuous Operations	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Pretax Income	$13,273,683	$-34,105,309	$-42,193,786	$-18,715,175
Interest Income Non Operating	$1,432,032	$1,285,998	$584,966	$71,072
Operating Income	$-48,953,363	$-42,910,520	$-38,075,320	$-28,917,617
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-0.79	$-3.68	$-7.64	$-4.31
Basic EPS	$0.22	$-3.68	$-7.64	$-4.31
Other
Tax Effect Of Unusual Items	$0	$0	$0	$2,183,832
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-46,158,253	$-34,379,322	$-33,309,983	$-25,520,913
Total Unusual Items	$62,754,186	$5,385,009	$-4,823,237	$10,399,200
Total Unusual Items Excluding Goodwill	$62,754,186	$5,385,009	$-4,823,237	$10,399,200
Reconciled Depreciation	$3,081,586	$4,792,595	$3,745,282	$3,291,878
EBITDA (Bullshit earnings)	$16,595,933	$-28,994,313	$-38,133,220	$-15,121,713
EBIT	$13,514,347	$-33,786,908	$-41,878,502	$-18,413,591
Diluted Average Shares	$61,340,193	$9,261,918	$5,521,487	$4,352,497
Basic Average Shares	$19,311,798	$9,261,918	$5,521,487	$4,352,497
Diluted NI Availto Com Stockholders	$-48,726,390	$-34,105,309	$-42,193,786	$-18,740,804
Gain On Sale Of Security	$62,754,186	$5,385,009	$-4,823,237	$10,399,200
Research And Development	$34,352,332	$30,251,667	$16,515,005	$36,438,513
Selling General And Administration	$14,601,031	$13,981,263	$23,799,306	$16,383,285
Other Gand A	$14,601,031	$13,981,263	$23,799,306	$16,383,285
Tax Provision	-	-	$0	$25,629
Other Special Charges	-	-	-	-

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$151,494,375	$25,969,576	$57,299,441	$31,058,142
Total Assets	$172,809,969	$44,195,469	$83,941,253	$50,904,927
Total Non Current Assets	$71,757,345	$20,403,240	$25,034,390	$28,807,474
Non Current Prepaid Assets	$5,309,345	$220,997	$350,230	$467,694
Non Current Deferred Assets	$150,145	$261,105	$0	-
Investmentin Financial Assets	$46,892,882	$0	-	-
Current Assets	$101,052,624	$23,792,229	$58,906,863	$22,097,453
Other Current Assets	$3,513,384	$2,976,562	$2,340,797	$1,493,982
Receivables	$946,781	$54,955	$0	$5,556,577
Accrued Interest Receivable	$946,781	$54,955	$0	-
Cash Cash Equivalents And Short Term Investments	$96,592,459	$20,760,712	$56,566,066	$15,046,894
Cash And Cash Equivalents	$10,502,680	$8,897,966	$56,566,066	$15,046,894
Accounts Receivable	-	-	$0	$5,556,577
Restricted Cash	-	-	-	$0
Prepaid Assets	-	-	-	$1,493,982
Debt
Total Debt	$5,950,681	$4,668,909	$5,907,059	$5,928,758
Long Term Debt And Capital Lease Obligation	$4,999,312	$3,857,067	$4,054,260	$4,532,511
Current Debt And Capital Lease Obligation	$951,369	$811,842	$1,852,799	$1,396,247
Current Debt	-	$275,849	$1,050,849	$772,665
Long Term Debt	-	-	-	$541,644
Other Current Borrowings	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$21,315,594	$18,225,893	$26,641,812	$19,846,785
Total Non Current Liabilities Net Minority Interest	$10,634,424	$10,246,293	$15,828,495	$4,853,441
Derivative Product Liabilities	$5,635,112	$6,389,226	$11,774,235	$320,930
Current Liabilities	$10,681,170	$7,979,600	$10,813,317	$14,993,344
Current Notes Payable	$0	$275,849	$1,050,849	$772,665
Payables And Accrued Expenses	$9,729,801	$7,167,758	$7,638,108	$12,134,924
Interest Payable	$21,075	$22,443	$77,995	$8,192
Payables	$3,145,805	$2,173,972	$2,407,076	$8,639,616
Accounts Payable	$3,145,805	$1,694,722	$945,927	$3,679,116
Current Deferred Liabilities	-	$0	$1,322,410	$0
Other Payable	-	$479,250	$1,461,149	$4,910,500
Total Tax Payable	-	-	$40,000	$50,000
Other Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$151,494,308	$25,969,571	$57,299,436	$31,058,142
Preferred Stock Equity	$67	$5	$5	-
Total Equity Gross Minority Interest	$151,494,375	$25,969,576	$57,299,441	$31,058,142
Stockholders Equity	$151,494,375	$25,969,576	$57,299,441	$31,058,142
Gains Losses Not Affecting Retained Earnings	$186,510	$-135,410	$26,420	$0
Other Equity Adjustments	$186,510	$-135,410	$26,420	-
Retained Earnings	$-110,895,167	$-124,168,850	$-90,063,541	$-47,869,755
Other
Treasury Shares Number	$54,665	$54,665	$54,665	$54,665
Ordinary Shares Number	$47,609,899	$9,288,868	$9,225,494	$5,039,426
Share Issued	$47,664,564	$9,343,533	$9,280,159	$5,094,091
Tangible Book Value	$151,494,308	$25,969,571	$57,299,436	$31,058,142
Invested Capital	$151,494,308	$26,245,420	$58,350,285	$32,372,451
Working Capital	$90,371,454	$15,812,629	$48,093,546	$7,104,109
Capital Lease Obligations	$5,950,681	$4,393,060	$4,856,210	$4,614,449
Total Capitalization	$151,494,375	$25,969,576	$57,299,441	$31,599,786
Treasury Stock	$5,521,246	$5,521,246	$5,521,246	$5,521,246
Additional Paid In Capital	$267,719,445	$155,794,142	$152,856,874	$84,448,633
Capital Stock	$4,833	$940	$934	$510
Common Stock	$4,766	$935	$929	$510
Preferred Stock	$67	$5	$5	$0
Long Term Capital Lease Obligation	$4,999,312	$3,857,067	$4,054,260	$3,990,867
Current Capital Lease Obligation	$951,369	$535,993	$801,950	$623,582
Current Accrued Expenses	$6,583,996	$4,993,786	$5,231,032	$3,495,308
Investments And Advances	$46,892,882	$0	-	-
Available For Sale Securities	$46,892,882	-	-	-
Net PPE	$19,404,973	$19,921,138	$24,684,160	$28,339,780
Accumulated Depreciation	$-17,516,462	$-14,573,924	$-9,911,859	$-6,278,522
Gross PPE	$36,921,435	$34,495,062	$34,596,019	$34,618,302
Leases	$7,064,721	$7,064,721	$9,296,344	$9,296,343
Construction In Progress	$759,279	$0	$0	$308,317
Other Properties	$17,438,911	$15,897,136	$14,362,851	$14,089,041
Machinery Furniture Equipment	$11,658,524	$11,533,205	$10,936,824	$10,924,601
Properties	$0	$0	$0	$0
Other Short Term Investments	$86,089,779	$11,862,746	$0	-
Current Deferred Revenue	-	$0	$1,322,410	$0
Pensionand Other Post Retirement Benefit Plans Current	-	-	$2,987,365	$1,462,173
Dueto Related Parties Current	-	-	-	$0

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-45,708,267	$-34,629,271	$-25,316,559	$-25,625,925
Operating Activities
Operating Cash Flow	$-44,775,111	$-34,292,009	$-25,119,405	$-23,459,511
Cash Flow From Continuing Operating Activities	$-44,775,111	$-34,292,009	$-25,119,405	$-23,459,511
Operating Gains Losses	$-62,828,153	$-5,385,009	$4,867,730	$-10,415,005
Investing Activities
Capital Expenditure	$-933,156	$-337,262	$-197,154	$-2,166,414
Investing Cash Flow	$-121,706,130	$-11,962,267	$-152,704	$-2,090,024
Cash Flow From Continuing Investing Activities	$-121,706,130	$-11,962,267	$-152,704	$-2,090,024
Financing Activities
Issuance Of Capital Stock	$168,729,827	$0	$7,500,000	$7,680,799
Financing Cash Flow	$168,299,452	$-1,172,626	$66,773,137	$1,051,411
Cash Flow From Continuing Financing Activities	$168,299,452	$-1,172,626	$66,773,137	$1,051,411
Net Other Financing Charges	$-11,963	$-286,036	-	$34,340,225
Net Common Stock Issuance	$168,729,827	$0	$0	$2,159,553
Common Stock Issuance	$168,729,827	$0	$0	$7,680,799
Net Preferred Stock Issuance	-	$0	$7,500,000	$0
Preferred Stock Issuance	-	$0	$7,500,000	$0
Repurchase Of Capital Stock	-	-	$0	$-5,521,246
Other
Repayment Of Debt	$-418,412	$-1,422,985	$-1,155,639	$-2,421,238
Issuance Of Debt	$0	$515,986	$765,194	$1,236,125
Interest Paid Supplemental Data	$242,032	$373,954	$245,481	$293,392
End Cash Position	$10,502,680	$8,897,966	$56,566,066	$15,046,894
Beginning Cash Position	$8,897,966	$56,566,066	$15,046,894	$39,545,018
Effect Of Exchange Rate Changes	$-213,497	$-241,198	$18,144	$0
Changes In Cash	$1,818,211	$-47,426,902	$41,501,028	$-24,498,124
Proceeds From Stock Option Exercised	$0	$20,409	$59,663,582	$76,971
Net Issuance Payments Of Debt	$-418,412	$-906,999	$-390,445	$-1,185,113
Net Short Term Debt Issuance	$-275,849	$-1,290,982	-	-
Short Term Debt Payments	$-275,849	$-1,290,982	-	-
Net Long Term Debt Issuance	$-142,563	$383,983	$-390,445	$-1,185,113
Long Term Debt Payments	$-142,563	$-132,003	$-1,155,639	$-2,421,238
Long Term Debt Issuance	$0	$515,986	$765,194	$1,236,125
Net Investment Purchase And Sale	$-120,773,474	$-11,625,005	$0	-
Sale Of Investment	$21,262,086	$25,821,196	$0	-
Purchase Of Investment	$-142,035,560	$-37,446,201	$0	-
Net PPE Purchase And Sale	$-932,656	$-337,262	$-152,704	$-2,090,024
Sale Of PPE	$500	$0	$44,450	$76,390
Purchase Of PPE	$-933,156	$-337,262	$-197,154	$-2,166,414
Change In Working Capital	$-3,685,348	$-2,298,989	$2,326,219	$-237,575
Change In Other Working Capital	$67,420	$-1,345,868	$1,709,709	$-100,000
Change In Payables And Accrued Expense	$2,424,317	$-307,705	$-4,416,457	$-3,319,699
Change In Accrued Expense	$941,524	$-1,231,028	$-1,714,737	$-2,537,907
Change In Payable	$1,482,793	$923,323	$-2,701,720	$-781,792
Change In Account Payable	$1,482,793	$923,323	$-2,701,720	$-779,425
Change In Prepaid Assets	$-5,285,259	$-590,461	$-523,610	$674,552
Change In Receivables	$-891,826	$-54,955	$5,556,577	$2,454,131
Other Non Cash Items	$172,474	$-237,093	$3,711,430	$-32,208
Stock Based Compensation	$5,210,647	$2,941,796	$2,423,720	$2,674,203
Depreciation Amortization Depletion	$3,081,586	$4,792,595	$3,745,282	$3,291,878
Depreciation And Amortization	$3,081,586	$4,792,595	$3,745,282	$3,291,878
Depreciation	$3,081,586	$4,792,595	$3,745,282	$3,291,878
Gain Loss On Investment Securities	$-62,828,153	$-5,385,009	$4,823,237	$-10,399,200
Net Income From Continuing Operations	$13,273,683	$-34,105,309	$-42,193,786	$-18,740,804
Changes In Account Receivables	-	$0	$5,556,577	$2,454,131
Gain Loss On Sale Of PPE	-	$0	$44,493	$-15,805
Common Stock Payments	-	-	$0	$-5,521,246
Change In Other Current Assets	-	-	$387,299	$53,441

Fetched: 2026-06-19